Safety & Efficacy Evaluation of a Radiofrequency & Laser/Light System for Improvement of Skin Texture
This study is currently recruiting participants.
Verified December 2011 by Candela Corporation
Sponsor:
Candela Corporation
Information provided by (Responsible Party):
Candela Corporation
ClinicalTrials.gov Identifier:
NCT01597323
First received: May 10, 2012
Last updated: NA
Last verified: December 2011
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Evaluate the clinical performance, safety and efficacy, of a Radiofrequency and Laser/Light based device for the treatment of facial wrinkles.
| Condition |
|---|
|
Skin Texture Irregularities Facial Skin Wrinkles |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Safety and Efficacy Evaluation of the eTWO System for Improvement of Skin Texture Via Skin Resurfacing and Wrinkles Reduction |
Further study details as provided by Candela Corporation:
Biospecimen Retention: Samples With DNA
Optional biopsy, for consenting subjects, of facial skin tissue from areas directly in front of ear (Pre-Auricular)
| Estimated Enrollment: | 150 |
| Study Start Date: | October 2011 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Treatment Group
Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial photodamage (sun damage) and presence of mild to moderate facial wrinkling
|
Eligibility| Ages Eligible for Study: | 35 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial photodamage (sun damage) and presence of mild to moderate facial wrinkling
Criteria
Inclusion Criteria:
- Healthy male or female between the ages of 35 and 60
- Non-smoker
- Fitzpatrick skin type I-VI
- Fitzpatrick Degree of Elastosis Score of 2-6 (inclusive)
- Presence of mild to moderate photodamage, such as solar lentigines, dyschromia and/or presence of mild to moderate facial wrinkling
- Able and willing to comply with all visit, treatment and evaluation schedules and requirements
- Able to understand and provide written Informed Consent
- Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment.
Exclusion Criteria:
- Pregnant or intending to become pregnant during the course of study. A urine pregnancy test will be given to women of childbearing potential and performed during initial visit;
- Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator
- Having a permanent implant in the treated area, such as metal plates and screws
- Unable or unlikely to refrain from tanning, including the use of tanning booths, during the course of the study
- Prior use of retinoids in treated area within 2 weeks of initial treatment or during the course of the study
- Use of oral Isotretinoin (Accutane®) within 6 months of initial treatment or during the course of the study
- Patient on systemic corticosteroid therapy 6 months prior to and throughout the course of the study
- Having received a facial dermabrasion or chemical peel treatment within 3 months of treatment or during the study
- Prior skin treatment with laser in treated area within 3 months of initial treatment or during the course of the study
- Prior use of Botox, collagen, fat injections and /or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 3-4 weeks of initial treatment or during the course of the study. Treatment may not be performed at all over permanent dermal implants
- Prior ablative resurfacing procedure, brow lift, blepharoplasty or face lift in treated area with laser or other devices within 12 months of initial treatment or during the course of the study
- Any other surgery in treated area within 12 months of initial treatment or during the course of the study
- History of keloid formation or poor wound healing in a previously injured skin area
- History of epidermal or dermal disorders (particularly if involving collagen or microvascularity)
- Open laceration or abrasion of any sort on the area to be treated
- Active Herpes Simplex I at the time of treatment
- Multiple dysplastic nevi in the area to be treated
- Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to the treatment (as per the subject 's physician discretion)
- History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications
- Having any form of active cancer at the time of enrollment and during the course of the study
- Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process
- Participation in a study of another device or drug within 1 month prior to study enrollment or during this study, and as per the Investigator's careful discretion, as long as not contradictory to any of the above criteria
- Tattoos, including cosmetic make-up tattoos, in the treatment area
- Mentally incompetent, prisoner or evidence of active substance or alcohol abuse
- Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01597323
Locations
| United States, Florida | |
| Sanctuary Medical Aesthetic Center | Recruiting |
| Boca Raton, Florida, United States, 33431 | |
| Contact: Diane Paquet 561-886-0970 dpaquet28@aol.com | |
| Principal Investigator: Jason N Pozner, MD | |
| United States, Maryland | |
| The Maryland Laser, Skin and Vein Institute | Completed |
| Hunt Valley, Maryland, United States, 21030 | |
| United States, New York | |
| Cosmetic & Reconstructive Plastic Surgery | Recruiting |
| Great Neck, New York, United States, 11021 | |
| Contact: Cindi Godt, RN 516-498-2804 | |
| Principal Investigator: Alan H Gold, MD | |
Sponsors and Collaborators
Candela Corporation
Investigators
| Principal Investigator: | Alan H Gold, MD | Board Certified Plastic Surgeon, American Board of Plastic Surgeons |
| Principal Investigator: | Robert Weiss, MD | Board Certified Dermatologist, American Board of Medical Specialties |
| Principal Investigator: | Jason N Pozner, MD | Board Certified Plastic Surgeon, American Board of Plastic Surgeons |
More Information
No publications provided
| Responsible Party: | Candela Corporation |
| ClinicalTrials.gov Identifier: | NCT01597323 History of Changes |
| Other Study ID Numbers: | DC84611 |
| Study First Received: | May 10, 2012 |
| Last Updated: | May 10, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Candela Corporation:
|
Wrinkle Reduction Skin Resurfacing Skin Texture Improvement |
ClinicalTrials.gov processed this record on June 13, 2013